Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 21705482)

1.

Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice.

Raufman JP, Shant J, Xie G, Cheng K, Gao XM, Shiu B, Shah N, Drachenberg CB, Heath J, Wess J, Khurana S.

Carcinogenesis. 2011 Sep;32(9):1396-402. doi: 10.1093/carcin/bgr118. Epub 2011 Jun 24.

2.

Scopolamine treatment and muscarinic receptor subtype-3 gene ablation augment azoxymethane-induced murine liver injury.

Khurana S, Shah N, Cheng K, Shiu B, Samimi R, Belo A, Shant J, Drachenberg C, Wess J, Raufman JP.

J Pharmacol Exp Ther. 2010 Jun;333(3):639-49. doi: 10.1124/jpet.109.165118. Epub 2010 Mar 2.

3.

Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia.

Cheng K, Xie G, Khurana S, Heath J, Drachenberg CB, Timmons J, Shah N, Raufman JP.

Mol Cancer. 2014 Apr 3;13:77. doi: 10.1186/1476-4598-13-77.

4.

Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor.

Smith DL, Keshavan P, Avissar U, Ahmed K, Zucker SD.

Carcinogenesis. 2010 Jun;31(6):1100-9. doi: 10.1093/carcin/bgq050. Epub 2010 Mar 1.

5.

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, Smith NR, Mandir N, Watkins AJ, Wilkinson RW.

Carcinogenesis. 2006 Oct;27(10):2133-9. Epub 2006 Jun 16.

6.

Haploinsufficiency of Krüppel-like factor 5 rescues the tumor-initiating effect of the Apc(Min) mutation in the intestine.

McConnell BB, Bialkowska AB, Nandan MO, Ghaleb AM, Gordon FJ, Yang VW.

Cancer Res. 2009 May 15;69(10):4125-33. doi: 10.1158/0008-5472.CAN-08-4402. Epub 2009 May 12.

7.

Cables1 is a tumor suppressor gene that regulates intestinal tumor progression in Apc(Min) mice.

Arnason T, Pino MS, Yilmaz O, Kirley SD, Rueda BR, Chung DC, Zukerberg LR.

Cancer Biol Ther. 2013 Jul;14(7):672-8. doi: 10.4161/cbt.25089. Epub 2013 May 31.

8.

Vitamin D receptor deficiency enhances Wnt/β-catenin signaling and tumor burden in colon cancer.

Larriba MJ, Ordóñez-Morán P, Chicote I, Martín-Fernández G, Puig I, Muñoz A, Pálmer HG.

PLoS One. 2011;6(8):e23524. doi: 10.1371/journal.pone.0023524. Epub 2011 Aug 15.

9.

Cholinergic muscarinic receptor activation augments murine intestinal epithelial cell proliferation and tumorigenesis.

Peng Z, Heath J, Drachenberg C, Raufman JP, Xie G.

BMC Cancer. 2013 Apr 24;13:204. doi: 10.1186/1471-2407-13-204.

10.

Myh deficiency enhances intestinal tumorigenesis in multiple intestinal neoplasia (ApcMin/+) mice.

Sieber OM, Howarth KM, Thirlwell C, Rowan A, Mandir N, Goodlad RA, Gilkar A, Spencer-Dene B, Stamp G, Johnson V, Silver A, Yang H, Miller JH, Ilyas M, Tomlinson IP.

Cancer Res. 2004 Dec 15;64(24):8876-81.

11.
12.

Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc Min/+ mouse model of intestinal cancer.

Volate SR, Muga SJ, Issa AY, Nitcheva D, Smith T, Wargovich MJ.

Mol Carcinog. 2009 Oct;48(10):920-33. doi: 10.1002/mc.20542.

13.

Disruption of estrogen receptor signaling enhances intestinal neoplasia in Apc(Min/+) mice.

Cleveland AG, Oikarinen SI, Bynoté KK, Marttinen M, Rafter JJ, Gustafsson JA, Roy SK, Pitot HC, Korach KS, Lubahn DB, Mutanen M, Gould KA.

Carcinogenesis. 2009 Sep;30(9):1581-90. doi: 10.1093/carcin/bgp132. Epub 2009 Jun 11.

14.

Inactivation of the vitamin D receptor in APC(min/+) mice reveals a critical role for the vitamin D receptor in intestinal tumor growth.

Zheng W, Wong KE, Zhang Z, Dougherty U, Mustafi R, Kong J, Deb DK, Zheng H, Bissonnette M, Li YC.

Int J Cancer. 2012 Jan 1;130(1):10-9. doi: 10.1002/ijc.25992. Epub 2011 Apr 20.

15.

Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.

Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST.

Cancer Res. 2008 May 15;68(10):3655-61. doi: 10.1158/0008-5472.CAN-07-2940.

16.

Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.

Alferez DG, Ryan AJ, Goodlad RA, Wright NA, Wilkinson RW.

Int J Oncol. 2010 Oct;37(4):767-72.

PMID:
20811697
17.

Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9.

Ramocki NM, Wilkins HR, Magness ST, Simmons JG, Scull BP, Lee GH, McNaughton KK, Lund PK.

Endocrinology. 2008 Jan;149(1):261-7. Epub 2007 Oct 4.

18.

Deletion of the AU-rich RNA binding protein Apobec-1 reduces intestinal tumor burden in Apc(min) mice.

Blanc V, Henderson JO, Newberry RD, Xie Y, Cho SJ, Newberry EP, Kennedy S, Rubin DC, Wang HL, Luo J, Davidson NO.

Cancer Res. 2007 Sep 15;67(18):8565-73.

19.

Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea.

Ju J, Hong J, Zhou JN, Pan Z, Bose M, Liao J, Yang GY, Liu YY, Hou Z, Lin Y, Ma J, Shih WJ, Carothers AM, Yang CS.

Cancer Res. 2005 Nov 15;65(22):10623-31.

20.

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice.

Alferez D, Wilkinson RW, Watkins J, Poulsom R, Mandir N, Wedge SR, Pyrah IT, Smith NR, Jackson L, Ryan AJ, Goodlad RA.

Mol Cancer Ther. 2008 Mar;7(3):590-8. doi: 10.1158/1535-7163.MCT-07-0433.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk